JAKARTA - Research published in the leading medical journal 'The Lancet' confirms the high safety profile of Russia's Sputnik Light single-dose COVID-19 vaccine, the Russian Direct Investment Fund (RDIF) announced on Wednesday.
"RDIF announces a new publication by the Gamaleya Center in The Lancet, one of the world's most respected medical journals, showing a single-dose Sputnik Light vaccine against the coronavirus exhibits a high safety profile and induces strong humoral and cellular immune responses", the statement said, launched TASS November 3.
Most of the adverse reactions observed during the study were mild or moderate. No serious adverse manifestations were detected, said the Russian Direct Investment Fund.
"Sputnik Light One-shot is a highly effective vaccine when used both alone and as a booster. Sputnik Light has been approved in more than 15 countries with registration processes underway in more than 30 countries", the statement continued.
Previous findings by the Gamaleya Center based on data from 28,000 people in Moscow showed that the self-administered Sputnik Light vaccine had 70 percent efficacy against the Delta variant of Coronavirus during the first three months after vaccination. In addition, the vaccine is 75 percent effective among individuals under the age of 60.
"Sputnik Light can be considered not only for primary vaccination but can also be useful as an efficient tool for booster dose vaccination or further vaccination after previous COVID-19 infection", the study said, citing KFGO.
Earlier, last week Russian Health Minister, Mikhail Murashko, said with the spread of the Delta variant, the ministry recommended the use of Sputnik Light for booster dose vaccinations.
The Kremlin later said Sputnik Light was a standalone COVID-19 vaccine, but some regions of Russia reported they had started giving it only to people with antibodies.
SEE ALSO:
To note, Sputnik Light was approved for clinical use in Russia on May 6 based on trial results published in 'The Lancet' and Gamaleya has started an international, placebo-controlled phase III study with 6,000 participants.
"We believe the Sputnik Light vaccine can contribute to accelerating vaccination rates in Russia as well as in other countries that lack sufficient vaccine supply", the scientists wrote.
The publication of this initial research in a top Western journal is a milestone, as Russia moves to make Sputnik Light its primary vaccine for export.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
Most Popular Tags
#Prabowo Subianto #golkar #OTT KPK #Pilkada Dki #online gamblingPopular
